Roche (ROG) PT Set at CHF 260 by UBS Group
UBS Group set a CHF 260 price objective on Roche (VTX:ROG) in a research report released on Monday morning, www.boersen-zeitung.de reports. The firm currently has a neutral rating on the healthcare company’s stock.
ROG has been the subject of a number of other research reports. Deutsche Bank set a CHF 255 price objective on Roche and gave the company a neutral rating in a research note on Monday, September 11th. Berenberg Bank set a CHF 260 price objective on Roche and gave the company a neutral rating in a research note on Tuesday, October 24th. JPMorgan Chase & Co. reiterated a buy rating on shares of Roche in a research note on Monday, October 9th. Morgan Stanley set a CHF 260 price objective on Roche and gave the company a neutral rating in a research note on Friday, October 6th. Finally, Jefferies Group set a CHF 295 price objective on Roche and gave the company a buy rating in a research note on Monday, October 16th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company. Roche currently has an average rating of Hold and a consensus target price of CHF 263.42.
Roche (VTX:ROG) opened at CHF 247.20 on Monday. The firm has a market capitalization of $214,660.00 and a PE ratio of 21.97. Roche has a 52 week low of CHF 226.10 and a 52 week high of CHF 273.
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.